vinorelbine tartrate injection usp solution
sandoz canada incorporated - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine tartrate for injection solution
teva canada limited - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine tartrate for injection solution
pfizer canada ulc - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents
vinorelbine ebewe 10 mg/1 ml (as tartrate) injection vial
sandoz pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection, concentrated - excipient ingredients: nitrogen; water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
vinorelbine- vinorelbine injection, solution
hospira, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection, usp is indicated: none pregnancy category d risk summary vinorelbine can cause fetal harm when administered to a pregnant woman. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus. animal data in a mouse embryofetal development study, administration of a single dose of vinorelbine at a dose level of 9 mg/m2 or greater (approximately 0.33 times the recommended human dose based on body surface area) was embryotoxic and fetotoxic. vinorelbine was embryotoxic and fetotoxic to pregnant rabbits when administered every 6 days during the period of organogenesis at doses of 5.5 mg/m2 (approximately 0.18 times the recommended human dose based on body surface area) or greater. at doses t
vinorelbine ag vinorelbine (as tartrate) 50 mg/5 ml concentrated injection vial
medtas pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
vinorelbine ag vinorelbine (as tartrate) 10 mg/1 ml concentrated injection vial
medtas pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
vinorelbine agila vinorelbine (as tartrate) 50 mg/5 ml concentrated injection vial
alphapharm pty ltd - vinorelbine tartrate -
vinorelbine agila vinorelbine (as tartrate) 10 mg/1 ml concentrated injection vial
alphapharm pty ltd - vinorelbine tartrate -
vinorelbine an vinorelbine (as tartrate) 50 mg/5 ml concentrated injection vial
amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 69.25 mg (equivalent: vinorelbine, qty 50 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.